ADVL1111: A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ...More

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL.

  • Conditions: Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some ...More

BRF116013: A Phase I/IIa, 2 Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Patients Aged 1 Month to <18 years with Advanced BRAF V600-Mutation Positive Solid Tumors.

  • Conditions: Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

PURPOSE:   This is a 2-part, study to determine the safety, tolerability and pharmacokinetics of oral dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. Part 1 (dose escalation study) will identify the recommended Part 2 (tumor-specific expansion study ...More

CLDK378X2103: A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies that have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK).

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

CLDK378X2103: A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies that have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK).  ...More

MEKINHIBITOR: A Phase I Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor AZD6244 Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN).

  • Conditions: Cancer - Neurofibromatosis Tumors
  • Gender: Female, Male

Background: Plexiform neurofibromas are tumors that grow in and around nerves. The only way to treat them is with surgery. Some of these tumors cannot be completely removed. The tumors may be too large, too numerous, or in a bad location for surgery. An experimental drug called AZD6244 hydrogen sul ...More

Neurofibromatosis Type 1 (NF1) Study

  • Conditions: Cancer - Neurofibromatosis Tumors
  • Gender: Female, Male

Cincinnati Children’s Hospital Medical Center is conducting is a research study, sometimes referred to as a clinical trial or clinical study, which measures brain activity in children with neurofibromatosis type 1 (NF1), to evaluate differences in learning and behavior in children and teenager ...More

NF 102/STOPN: A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type I Related Plexiform Neurofibromas

  • Conditions: Adult Studies, Cancer - Neurofibromatosis Tumors
  • Gender: Female, Male

This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morbidity. ...More

SARC 006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Neurofibromatosis Tumors
  • Gender: Female, Male

This phase II trial is studying how well combination chemotherapy works in treating patients with stage III or stage IV malignant peripheral nerve sheath tumors. ...More

Contact Us

hospital

Adult Participants or Parents of Participants:

Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at clinicalstudies@cchmc.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.

Sponsors and Investigators:

The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.